NHI coverage to expand to major cancer drugs.

Published: 2006-01-13 06:57:00

Updated: 2006-01-13 06:57:00

The NHI (national health insurance) reimbursement standards for anti-cancer drugs such as Iressa, Zeloda and Taxol inj. seem to be expanded.

The Cancer Disease Review Council of HIRA prepared detailed plans for the NHI coverage to cancer patients especially over chemotherapy, anti-vomiting and...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK